Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lipton

Showing results (1001-1010 of 1,173) with videos related to

Pageof 118
Sort By:
Cephalalgia : an International Journal of Headache|December 1, 1993
Headache and cortisol responses to m-chlorophenylpiperazine are highly correlatedM L Gordon, R B Lipton, S L Brown, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
The New England Journal of Medicine|July 11, 2019
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for MigraineRichard B Lipton, Robert Croop, Elyse G Stock, et al.
Headache|March 6, 2013
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Andrew M Blumenfeld, Lisa M Bloudek, Werner J Becker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Headache-related health resource utilisation in chronic and episodic migraine across six countriesJoanna C Sanderson, Emily B Devine, Richard B Lipton, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
The Lancet. Neurology|March 9, 2010
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trialRichard B Lipton, David W Dodick, Stephen D Silberstein, et al.
Diagnosis (Berlin, Germany)|October 2, 2020
Head Computed tomography during emergency department treat-and-release visit for headache is associated with increased risk of subsequent cerebrovascular disease hospitalizationAva L Liberman, Cuiling Wang, Benjamin W Friedman, et al.
Headache|December 28, 2020
The migraine signature study: Methods and baseline resultsAlice R Pressman, Dawn C Buse, Alice S Jacobson, et al.
Pageof 118

Showing results (1001-1010 of 1,173) with videos related to

Sort By:
Pageof 118
Cephalalgia : an International Journal of Headache|December 1, 1993
Headache and cortisol responses to m-chlorophenylpiperazine are highly correlatedM L Gordon, R B Lipton, S L Brown, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
The New England Journal of Medicine|July 11, 2019
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for MigraineRichard B Lipton, Robert Croop, Elyse G Stock, et al.
Headache|March 6, 2013
Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)Andrew M Blumenfeld, Lisa M Bloudek, Werner J Becker, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
Headache-related health resource utilisation in chronic and episodic migraine across six countriesJoanna C Sanderson, Emily B Devine, Richard B Lipton, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
The Lancet. Neurology|March 9, 2010
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trialRichard B Lipton, David W Dodick, Stephen D Silberstein, et al.
Diagnosis (Berlin, Germany)|October 2, 2020
Head Computed tomography during emergency department treat-and-release visit for headache is associated with increased risk of subsequent cerebrovascular disease hospitalizationAva L Liberman, Cuiling Wang, Benjamin W Friedman, et al.
Headache|December 28, 2020
The migraine signature study: Methods and baseline resultsAlice R Pressman, Dawn C Buse, Alice S Jacobson, et al.
Pageof 118